Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore
Expert Review of Pharmacoeconomics & Outcomes Research · 2024
DOI: 10.1080/14737167.2023.2295474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Elaine Hsuen Lim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Breast Neoplasms, Biosimilar Pharmaceuticals, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche Singapore Pte Ltd.
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVES: The Asian PEONY trial showed that add-on pertuzumab to trastuzumab and chemotherapy significantly improved pathological complete response in the neoadjuvant treatment of patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC). This study evaluated the cost-effectiveness of pertuzumab as an add-on therapy to trastuzumab and chemotherapy for neoadjuvant treatment of patients with HER2+ EBC in Singapore. METHODS: A six-state Markov model was developed from the Singapore healthcare system perspective, with a lifetime time horizon. Model outputs were: costs; life-years (LYs); quality-adjusted LYs (QALYs); incremental cost-effectiveness ratios (ICERs). Sensitivity/scenario analyses explored model uncertainties. RESULTS: The base case projected the addition of pertuzumab to be associated with improved outcomes by 0.277 LYs and 0.271 QALYs, increased costs by S$1,387, and an ICER of S$5,121/QALY. The ICER was most sensitive to the pCR rate, and the probabilistic sensitivity analysis showed that add-on pertuzumab had an 81.3% probability of being cost-effective at a willingness-to-pay threshold of S$45,000/QALY gained. CONCLUSIONS: This model demonstrated that the long-term clinical impact of early pertuzumab use, particularly the avoidance of metastatic disease and thus avoidance of higher costs and mortality rates, make neoadjuvant pertuzumab a cost-effective option in the management of patients with HER2+ breast cancer in Singapore.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
- Asia-Pacific Evidence Development, Costello Medical Singapore Pte Ltd, Singapore, Singapore.
- Medical, Roche Singapore Pte Ltd, Singapore, Singapore.
- Market Access, Roche Singapore Pte Ltd, Singapore, Singapore.
- HTA, Costello Medical Consulting Ltd, London, UK.
- Health Economics, Costello Medical Consulting Ltd, London, UK.
Förderung
- Roche Singapore Pte Ltd
Zitieren
APA
Lim, E. H., Lim, A., Khara, J. S., Cheong, J., Fong, J., Sivanesan, S., Griffiths, M., New, E., & Lee, S. C. (2024). Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2023.2295474
Vancouver
Lim EH, Lim A, Khara JS, Cheong J, Fong J, Sivanesan S, et al. Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2023.2295474
BibTeX
@article{Lim2024,
author = {Lim, Elaine Hsuen and Lim, Andrew and Khara, Jasmeet Singh and Cheong, John and Fong, Jek and Sivanesan, Sivabalan and Griffiths, Matt and New, Emma and Lee, Soo Chin},
title = {Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2024},
doi = {10.1080/14737167.2023.2295474}
}
EUVIMED